Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System

Abstract

Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further "neurobiological targeted" approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

Overview

Integrity signals

Registry

Crossref · 10.2174/1381612825666190312102444

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Research works printed but not linked: 2

  1. .
  2. Berman RM, Cappiello A, Anand A. Antidepressant effects of ketamine in depressed patients. · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., Vellante, F., Martinotti, G., Giannantonio, M. D., Kim, Y.-K., Nicola, M. D., Bellomo, A., Ventriglio, A., Fornaro, M., & Berardis, D. D.
Affiliations
  • NHS, Department of Mental Health ASL Teramo, Psychiatric Service of Diagnosis and Treatment, Hospital “Maria SS dello Splendore”, Giulianova, Italy
  • Department of Neuroscience, Imaging and Clinical Science, University , Italy
  • NHS, Department of Mental Health ASUR Marche AV5, Mental Health Unit, Ascoli Piceno, Italy
  • Polyedra Research Group, Teramo, Italy
  • Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “Madonna Del Soccorso,” NHS, San Benedetto del Tronto, Ascoli Piceno, Italy
  • Azienda Ospedaliera Sant'Andrea (IT)
  • Ospedale Policlinico San Martino (IT)
  • Hermanas Hospitalarias del Sagrado Corazón de Jesús (IT)
  • Korea University (KR)
  • Università Cattolica del Sacro Cuore (IT)
  • University of Foggia (IT)
  • Federico II University Hospital (IT)
Corresponding author
Berardis, Domenico D.
Venue
Current Pharmaceutical Design
Published
2019-06-03
Volume
25
Issue
4
Pages
381-387
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2922005496
Cited by
44
References
75
Citations by year
2026: 4 · 2025: 6 · 2024: 1 · 2023: 10 · 2022: 9 · 2021: 4 · 2020: 8 · 2019: 2
FWCI
0.73
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
major depressive disorder, glutamatergic system, glutamate, depression pathophysiology, ketamine, monoamine hypothesis, treatment-resistant depression, antidepressant treatment
MeSH terms
Depression, Major Depressive Disorder, Humans, Ketamine, Synaptic Transmission, Excitatory Amino Acid Agents, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. https://app.cochat.ai/papers/10.2174/1381612825666190312102444
The paper
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., Vellante, F., Martinotti, G., Giannantonio, M. D., Kim, Y.-K., Nicola, M. D., Bellomo, A., Ventriglio, A., Fornaro, M., & Berardis, D. D. (2019). Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. Current Pharmaceutical Design. https://doi.org/10.2174/1381612825666190312102444

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.